J&J reaches pact with U.S. government over access to medicines

Johnson & Johnson announced a voluntary agreement with the Trump Administration to “improve access to medicines and lower costs for millions of American patients.” The joint agreement meets the requests laid out by President Trump to the industry and provides the Company’s pharmaceutical products an exemption from tariffs. “Today’s agreement shows that when the public and private sectors work together towards shared goals, we can deliver real results for patients and the U.S. economy,” said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. “I’m proud that Johnson & Johnson is answering President Trump’s call to lower drug prices for everyday Americans while maintaining our role in improving and saving lives and ensuring that the United States continues to lead the world in healthcare innovation.” Johnson & Johnson is working with the Trump Administration to improve access to medicines and lower costs for millions of American patients. The company is: Participating in TrumpRx.gov, a direct to patient platform; Enabling American patients to access medicines at comparable prices to other developed countries; Providing Medicaid program access at comparable prices to other developed countries, and; Continuing to support the Administration’s efforts to “ensure better recognition of the value of health care across developed markets globally.”